Akanocure Pharmaceuticals Inc.
West Lafayette, IN
- UEI
- QMU8ZFLN2A34
- CAGE
- 7AUB2
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 3495 Kent Ave, West Lafayette, IN 47906, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Sbir phase II: a novel host-directed broad-spectrum antiviral and efficient immunomodulatory agent against… | National Science Foundation | $1,000,000 | |
| Sbir phase i: AK-423: a broad-spectrum antiviral and immunomodulatory agent (covid-19) | National Science Foundation | $256,000 | |
| Sbir phase II: multiplex expansion of the chiral carbon catalog platform towards stereo-enriched non-propionate chemical… | Division of Industrial Innovation | $949,999 | |
| Sbir phase i: novel stereo-enriched libraries as commercial complex building blocks for facile development of… | Division of Industrial Innovation | $224,996 |
About Akanocure Pharmaceuticals Inc.
Akanocure Pharmaceuticals Inc. is a for-profit corporate entity registered in the System for Award Management (SAM.gov) since January 2015, with a registration valid through March 2025. The company appears to be a pharmaceutical research and development organization focused on developing innovative therapeutic solutions, particularly in the area of antiviral and immunomodulatory treatments. While limited publicly available information exists about the company's comprehensive background, its federal grant award history demonstrates a strong commitment to advancing scientific research through Small Business Innovation Research (SBIR) programs.
The company has received multiple federal grant awards from the National Science Foundation, primarily focusing on advanced pharmaceutical research and development. Its most recent and significant award is a $1,000,000 Cooperative Agreement for lead optimization studies of a novel, broad-spectrum antiviral and immunomodulatory agent targeting coronaviruses. Previous grants include a Phase I SBIR grant in 2021 for COVID-19 related research on an antiviral agent (AK-423), and a Phase II SBIR grant in 2020 for developing a chiral carbon catalog platform with potential industrial applications. These grants consistently demonstrate Akanocure's expertise in pharmaceutical innovation, with a particular emphasis on developing virus-agnostic therapeutic approaches that can suppress viral replication and modulate immune responses. The company's research appears to be strategically aimed at creating adaptable medical solutions that can address emerging viral threats and complex immune system challenges.
Quick answers
What is Akanocure Pharmaceuticals Inc.'s UEI?
Akanocure Pharmaceuticals Inc.'s Unique Entity ID (UEI) in SAM.gov is QMU8ZFLN2A34.
What is Akanocure Pharmaceuticals Inc.'s CAGE code?
Akanocure Pharmaceuticals Inc.'s CAGE code is 7AUB2.
Where is Akanocure Pharmaceuticals Inc. located?
Akanocure Pharmaceuticals Inc.'s physical address in SAM.gov is 3495 Kent Ave, West Lafayette, IN 47906, USA.
Is Akanocure Pharmaceuticals Inc. registered in SAM.gov?
Yes. Akanocure Pharmaceuticals Inc.'s SAM.gov registration is active through April 27, 2027.
What is Akanocure Pharmaceuticals Inc.'s most recent federal award?
Akanocure Pharmaceuticals Inc.'s most recent federal grant award is Sbir phase II: a novel host-directed broad-spectrum antiviral and efficient immunomodulatory agent against… (2325532), from National Science Foundation, on September 1, 2024.
On GovTribe
See Akanocure Pharmaceuticals Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors